Back

Does initiating SGLT2 inhibitors at an early stage of heart failure admission really reduce cardiovascular mortality and first rehospitalization? A meta-analysis of randomized controlled trials

29 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Acute heart failure therapies: timing, choices, and comparative effectiveness Pharmacotherapy ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Elena Alupei

(Romania)

4 More presentations in this session

Presentation thumbnail
Impact of levosimendan versus dobutamine on 30-day mortality and hospital stay in acute decompensated heart failure: a systematic review and meta-analysis
Doctor H. Amorim Parente (Rio de Janeiro, BR)
Abstract Slides Video
Presentation thumbnail
From trials to treatment: real-world vericiguat initiation and residual risk in Germany
Doctor F. Kerwagen (Wuerzburg, DE)
Abstract Slides Video
Presentation thumbnail
Early in-hospital initiation of dapagliflozin versus empagliflozin in acute heart failure: impact on in-hospital survival and safety
Doctor N. Benameur (Tangier, MA)
Abstract Slides Video
Presentation thumbnail
Early catheter ablation for atrial fibrillation in acute heart failure: prognostic impact across age and ejection fraction
Doctor A. Okahara (Fukuoka, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Acute heart failure therapies: timing, choices, and comparative effectiveness

The Event

Event poster

ESC Congress 2026

29 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Timing matters: clinical outcomes of early sodium-glucose cotransporter-2 inhibitor initiation in acute heart failure
10 May 2026
thumbnail
Congress Presentation
Impact of in-hospital initiation of sodium-glucose cotransporter-2 inhibitors in patients with heart failure and reduced ejection fraction
28 August 2023
thumbnail
Congress Presentation
Early SGLT2i therapy in patients with T2DM and ACS results in reduction in cardiovascular and renal outcomes- a propensity score matched multi-model retrospective registry analysis
30 August 2025
thumbnail
Congress Presentation
Initiation of SGLT2I during acute HF hospitalization or in the immediate period following discharge.
12 May 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources